Deutsche Bank Adjusts Danaher Price Target to $235 From $240

Published on 06/05/2025 at 08:55

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Danaher Corporation

Baird Adjusts Danaher Price Target to $226 From $225, Maintains Outperform Rating	Jul. 18	MT
Leerink Partners Adjusts Price Target on Danaher to $235 From $230, Maintains Outperform Rating	Jul. 17	MT
OraSure Technologies received takeover bid from industry entrepreneur, sources say	Jul. 14	RE
Scotiabank Upgrades Danaher to Sector Outperform From Sector Perform, Adjusts PT to $275 From $265	Jul. 11	MT
Evercore ISI Adjusts Price Target on Danaher to $226 From $230, Maintains Outperform Rating	Jul. 08	MT
Baxter International taps Andrew Hider as CEO	Jul. 07	RE
Wolfe Research Adjusts Danaher Price Target to $230 From $220, Maintains Outperform Rating	Jul. 01	MT
Danaher Corporation Appoints Martin Stumpe as Chief Technology and AI Officer, Effective October 1, 2025	Jun. 27	CI
Danaher Corporation Appoints Greg Milosevich to Executive Vice President, Life Sciences Business, Effective July 1, 2025	Jun. 27	CI
Danaher Names Martin Stumpe Chief Technology, AI Officer	Jun. 27	MT
Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index	Jun. 26	CI
Barclays Adjusts Danaher Price Target to $225 From $215	Jun. 24	MT
Some of the biggest splits in Corporate America	Jun. 09	RE
Some of the biggest splits in Corporate America	Jun. 09	RE
Deutsche Bank Adjusts Danaher Price Target to $235 From $240	Jun. 05	MT
Sciex And Evosep Expand Access To Standardized Proteomics For Pharma And Biotech With New Reseller Agreement	Jun. 02	RE
Software Launches For Sciex Os Ecosystem	Jun. 02	RE
AstraZeneca, Danaher to Develop New Precision Medicine Diagnostic Tools	May. 30	MT
Danaher partners with AstraZeneca to develop AI diagnostics	May. 30	AN
Danaher Announces Diagnostic Development And Commercialization Partnership To Scale Precision Medicine	May. 29	RE
Danaher, AstraZeneca Collaborate on Precision Medicine	May. 29	MT
Danaher Corporation Announces the Launch of Partnership with AstraZeneca to Develop and Commercialize Novel Diagnostic Tools and Tests Intended to Help Clinicians Better Determine Which Patients Would Most Benefit from Precision Medicine Treatments	May. 29	CI
Danaher, AstraZeneca Form Partnership For Diagnostic Development	May. 29	DJ
Third Point LLC Dissolves Share Stake In Meta, Thermo Fisher Scientific & Cuts Share Stake In Microsoft	May. 15	RE
Danaher Corporation Presents at BofA Securities 2025 Healthcare Conference, May-15-2025 10:00 AM	May. 15